Income statement
USD
Annual
| Metric | 2025 | 2024 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0 | 1M | 0 | 3M |
| Gross Profit | 0 | 0 | 0 | 3M |
| Operating Income | -49M | -43M | 0 | -9M |
| EBITDA | -49M | -43M | 0 | -8M |
| Net Income | 13M | -34M | 0 | -9M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$8.44
-19.23% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Big Cypress Acquisition Corp. (BCYP) is a Healthcare stock with a market cap of $425.36M. The stock last traded around $8.44. Baseline metrics include revenue growth of -100.0%, EPS growth of +106.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +106.0%, free cash flow -30.6% with operating margin 0.0% and ROIC -30.0%. Valuation is more restrained than many high-expectation growth names at P/E 12.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines BCYP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BCYP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BCYP Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BCYP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.4M
FY Net Income
-$9.0M
Free Cash Flow
-$9.8M
-260.2% YoY
Revenue Growth
-100.0%
EPS Growth
+106.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0 | 1M | 0 | 3M |
| Gross Profit | 0 | 0 | 0 | 3M |
| Operating Income | -49M | -43M | 0 | -9M |
| EBITDA | -49M | -43M | 0 | -8M |
| Net Income | 13M | -34M | 0 | -9M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2020 | 2019 |
|---|---|---|---|---|
| Cash & Equivalents | 11M | 9M | 85K | 6M |
| Total Assets | 173M | 44M | 322K | 18M |
| Total Liabilities | 21M | 18M | 306K | 20M |
| Shareholder Equity | 151M | 26M | 39M | -2M |
| Total Debt | 6M | 5M | 0 | 8M |
| Net Debt | -5M | -4M | -85K | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
-192.1% YoY
Capital Expenditures
609K
+95.2% YoY
Free Cash Flow
10M
-260.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
15.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.